NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
Clinical Trials
23 trialsNCT04504331 2026-02-12
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Phase 1 Terminated
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06320990 2025-06-08
MCN_Tam
University of Nebraska
Phase 1 Recruiting
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT05156892 2025-05-15
TICTOC
St Vincent's Hospital, Sydney
Phase 1 Active not recruiting
NCT00424164 2024-03-08
LAPATAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT04961632 2024-02-01
Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376
National Cancer Centre, Singapore
Phase 1 Unknown
NCT02333370 2023-06-08
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT04433494 2022-12-07
A Study of TY-302 in Patients With Advanced Solid Tumors
TYK Medicines, Inc
Phase 1 Unknown
NCT04200066 2022-08-22
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
University of Rochester
Phase 1 Withdrawn
NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02936206 2021-05-19
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated
NCT01192308 2020-12-01
KINETAM
Radboud University Medical Center
Phase 1 Completed
NCT01393990 2020-03-24
A Study of LY2228820 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02093351 2019-10-02
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
AstraZeneca
Phase 1 Completed
NCT01971515 2018-09-19
First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
EMD Serono
Phase 1 Completed
NCT02513849 2017-05-09
Tamoxifen in Patients With Oesophageal Cancer
University of Nottingham
Phase 1 Unknown
NCT00005886 2017-01-13
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
University of Kansas Medical Center
Phase 1 Completed
NCT00009997 2011-03-28
Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NYU Langone Health
Phase 1 Completed
NCT00003080 2010-09-15
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00005822 2010-06-11
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00001436 2008-03-04
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed